Head-to-head · WeighScore
Bodi Envi vs Maves
The verdict
Too close to call — both grade 71.8/100 (C).
Bodi Envi and Maves land on the same WeighScore, so neither clears the other on our six graded dimensions. Bodi Envi sits one line higher on the board (#88 vs #89) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Bodi Envi | Maves |
|---|---|---|
| WeighScore | 71.8/100 | 71.8/100 |
| Grade | C | C |
| Scorecard rank | #88 | #89 |
| Semaglutide | $179/mo | $99/mo (starting dose, first-month rate, compounded) |
| Tirzepatide | $249/mo | Not disclosed |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #88 · C
Strengths
- Transparent flat pricing: compounded semaglutide $179/month and tirzepatide $249/month, all doses
- No consultation or membership fees
- Free 2-day shipping included; FSA and HSA eligible
- 24/7 secure provider messaging with same-day visits and prescriptions
- Personalized dose titration with side-effect management (Zofran available)
Where it loses points
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
- No insurance billing — cash-pay only
- States served are not explicitly listed (features vary by state)
- No LegitScript certification visible on the site
Graded #89 · C
Strengths
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
- All 50 states covered, stated explicitly
- Both brand (Maves) and parent (Homera Health) disclosed for accountability
Where it loses points
- 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
- Tirzepatide pricing not stated on the homepage — only listed as an offering
- Named medical director / clinical leadership not disclosed
- Refund and cancellation policy not detailed publicly
- Corporate address and arbitration venue not disclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.